ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lorlatinib

Also written as “Lorlatinib”, “PF-06463922” and “Lorlatinib 50 mg”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma · Renal Insufficiency, led by 4 companies.

Drug pageLorlatinib: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 22, 202020 company-led studies, 5 open or runningNext primary completion: Nov 30, 2028

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer173 open or runningphase 4since Apr 22, 2020Oct 16, 2013Nov 30, 2028NCT06487078
CStone Pharmaceuticalsits history only11 open or runningphase 2since Mar 17, 2022Mar 17, 2022none ahead
Hoffmann-La Rocheits history only11 open or runningphase 1since May 14, 2026May 14, 2026Aug 31, 2030phase 1 · NCT07617337
Strata Oncologyits history only10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Merck and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Oct 16, 2013.

  1. Oct 21, 2015Phase 2 study in Carcinoma, Non-Small-Cell LungNCT02584634 · 43 enrolled · United States, Australia, Japan and more
  2. Dec 9, 2015Named lorlatinibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, PF-06463922
  3. Jun 10, 2016Phase 1 study in HealthyNCT02804399 · 12 enrolled · United States
  4. Jul 17, 2016Phase 1 study in HealthyNCT02838264 · 16 enrolled · Belgium
  5. Jan 20, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungNCT03052608 · 296 enrolled · United States, Argentina, Australia and more
  6. May 17, 2017Phase 1 study in Carcinoma, Non-Small-Cell LungNCT03184168 · 6 enrolled · United States
  7. May 18, 2018Phase 1 study in Renal InsufficiencyNCT03542305 · 29 enrolled · United States
  8. Sep 24, 2018Phase 1 study in NeoplasmsNCT03726333 · 1 enrolled · United States
  9. Feb 5, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03909971 · 109 enrolled · China
  10. May 22, 2019Phase 1 study in AdultNCT03961997 · 16 enrolled · Belgium
  11. Apr 22, 2020Phase 4 study in CarcinomaNCT04362072 · 71 enrolled · United States, India, Italy and more
  12. Aug 21, 2020Phase 4 study in Advanced Non-Small Cell Lung CancerNCT04541706 · 100 enrolled · India
  13. Nov 22, 2021Phase 4 study in Carcinoma, Non-Small-Cell LungNCT05144997 · 76 enrolled · United States, China, France and more
  14. Jan 24, 2022Phase 1 study in Moderate Hepatic ImpairmentNCT05224609 · 21 enrolled · United States
  15. Jun 5, 2024No phase study in ALK+ Non-Small-Cell Lung CarcinomaNCT06487078 · 90 planned · France

Ahead

  1. Nov 30, 2028Primary completion: no phase study in ALK+ Non-Small-Cell Lung CarcinomaNCT06487078
  2. Oct 25, 2029Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungNCT05144997

TargetBeta

ALK →EML4 →read by rule
“An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431

Studies

All 17 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06487078ALK+ Non-Small-Cell Lung Carcinoma · France–RecruitingNov 30, 202890
NCT05224609Moderate Hepatic Impairment · United States1CompletedAug 13, 202421
NCT05144997Carcinoma, Non-Small-Cell Lung · United States, China, France and more4Active, not recruitingOct 25, 202976
NCT04541706Advanced Non-Small Cell Lung Cancer · India4CompletedJul 20, 2022100
NCT04362072Carcinoma · United States, India, Italy and more4CompletedMay 29, 202471
NCT03961997Adult · Belgium1CompletedDec 9, 201916
NCT03909971Carcinoma, Non-Small-Cell Lung · China2CompletedAug 10, 2020109
NCT03726333Neoplasms · United States1TerminatedJul 8, 20211
NCT03542305Renal Insufficiency · United States1CompletedFeb 20, 202029
NCT03184168Carcinoma, Non-Small-Cell Lung · United States1CompletedAug 7, 20176
NCT03052608Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingMar 20, 2020296
NCT02838264Healthy · Belgium1CompletedMar 31, 201716
NCT02804399Healthy · United States1CompletedOct 201612
NCT02584634Carcinoma, Non-Small-Cell Lung · United States, Australia, Japan and more2TerminatedFeb 2, 202143
NCT02569554Healthy · Belgium1CompletedApr 201627
NCT02564562Healthy · United States1CompletedNov 20156
NCT01970865Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2CompletedMar 15, 2017364

How it is read

Names in the registry

  • “Lorlatinib”, 10 entries
  • “PF-06463922”, 8 entries
  • “lorlatinib”, 6 entries
  • “Lorlatinib 50 mg”, 1 entry
  • “Lorlatinib 75 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.